To assess safety and preliminary efficacy of adeno-associated virus vector serotype 2 containing glial cell–derived neurotrophic factor (AAV2-GDNF), AB-1005, in participants with mild or moderate Parkinson's disease (PD) administered using magnetic resonance imaging (MRI)-monitored, one-time bilateral, convection-enhanced delivery (CED).
No takes yet. Share an insight, caveat, or question.
Laar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: